Drugs / BAL0891
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05768932 | Dec 2022 → Dec 2026 expected | acute myeloid leukemia, gastric cancer, triple-negative breast carcinoma | SillaJen, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAL0891 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768932 ↗ |
| Action | Inhibit | “BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)” NCT05768932 ↗ |
| Route | Intravenous | “BAL0891 will be administered intravenously (IV) on Day (D) 1 and D8 every 3 weeks (Q3W)” NCT05768932 ↗ |
| Target | PLK1 | “BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)” NCT05768932 ↗ |
| Target | TTK | “BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)” NCT05768932 ↗ |